These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Complement and Complement Targeting Therapies in Glomerular Diseases. Andrighetto S; Leventhal J; Zaza G; Cravedi P Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31888179 [TBL] [Abstract][Full Text] [Related]
4. The role of complement in kidney disease. Petr V; Thurman JM Nat Rev Nephrol; 2023 Dec; 19(12):771-787. PubMed ID: 37735215 [TBL] [Abstract][Full Text] [Related]
5. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Anliker-Ort M; Dingemanse J; van den Anker J; Kaufmann P Front Immunol; 2020; 11():599417. PubMed ID: 33362783 [TBL] [Abstract][Full Text] [Related]
7. The role of the alternative pathway of complement activation in glomerular diseases. Łukawska E; Polcyn-Adamczak M; Niemir ZI Clin Exp Med; 2018 Aug; 18(3):297-318. PubMed ID: 29450785 [TBL] [Abstract][Full Text] [Related]
8. Role of complement in glomerular diseases. Mao S; Zhang J J Recept Signal Transduct Res; 2016; 36(3):319-25. PubMed ID: 26400225 [TBL] [Abstract][Full Text] [Related]
9. The role of complement in C3 glomerulopathy. Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733 [TBL] [Abstract][Full Text] [Related]
13. Molecules Great and Small: The Complement System. Mathern DR; Heeger PS Clin J Am Soc Nephrol; 2015 Sep; 10(9):1636-50. PubMed ID: 25568220 [TBL] [Abstract][Full Text] [Related]
14. [Complement system regulation and C3 glomerulopathy]. Xiao HJ; He RJ Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):323-6. PubMed ID: 23591359 [TBL] [Abstract][Full Text] [Related]
15. Complement and glomerular disease: new insights. Pickering M; Cook HT Curr Opin Nephrol Hypertens; 2011 May; 20(3):271-7. PubMed ID: 21422921 [TBL] [Abstract][Full Text] [Related]
16. Urinary complement biomarkers in immune-mediated kidney diseases. Kesarwani V; Bukhari MH; Kahlenberg JM; Wang S Front Immunol; 2024; 15():1357869. PubMed ID: 38895123 [TBL] [Abstract][Full Text] [Related]
17. Complement inhibitors for kidney disease. Wooden B; Tarragon B; Navarro-Torres M; Bomback AS Nephrol Dial Transplant; 2023 Nov; 38(Supplement_2):ii29-ii39. PubMed ID: 37218685 [TBL] [Abstract][Full Text] [Related]
18. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601 [TBL] [Abstract][Full Text] [Related]
19. The complement cascade and renal disease. Kościelska-Kasprzak K; Bartoszek D; Myszka M; Zabińska M; Klinger M Arch Immunol Ther Exp (Warsz); 2014 Feb; 62(1):47-57. PubMed ID: 24030732 [TBL] [Abstract][Full Text] [Related]